Hélène Cabanas

From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history

Hélène Cabanas, PhD, is a Cell physiologist participating in a post-doctorate fellowship at the School of Medical Sciences, Griffith Health, Griffith University, Australia.[1] She is a member of the National Centre for Neuroimmunology and Emerging Disease (NCNED), an Australian research group led by Professors Sonya Marshall-Gradisnik and Donald Staines.[2] Her research focuses on cellular calcium pathway signalling and their implications in physiological and pathophysiological processes in hopes of understanding the pathomechanism of Chronic Fatigue Syndrome / Myalgic Encephalomyelitis (CFS/ME).[2]

Notable studies[edit | edit source]

  • 2021, Potential Therapeutic Benefit of Low Dose Naltrexone in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Role of Transient Receptor Potential Melastatin 3 Ion Channels in Pathophysiology and Treatment[3] - (Full text)
  • 2021, Systematic Review of Sleep Characteristics in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome[4] - (Full text)
  • 2019, Validation of impaired Transient Receptor Potential Melastatin 3 ion channel activity in natural killer cells from Chronic Fatigue Syndrome/ Myalgic Encephalomyelitis patients[5] - (Full text)
  • 2019, A systematic review of cytokines in chronic fatigue syndrome/myalgic encephalomyelitis/systemic exertion intolerance disease (CFS/ME/SEID)[6] - (Full text)
  • 2019, Naltrexone restores impaired transient receptor potential melastatin 3 ion channel function in natural killer cells from myalgic encephalomyelitis/chronic fatigue syndrome patients[7] - (Abstract)
  • 2019, Transient receptor potential melastatin 2 channels are overexpressed in myalgic encephalomyelitis/chronic fatigue syndrome patients[8] - (Full text)

Talks and interviews[edit | edit source]

Online presence[edit | edit source]

See also[edit | edit source]

Learn more[edit | edit source]

References[edit | edit source]

  1. ↑ "Hélène Cabanas". LinkedIn. Retrieved October 21, 2019.
  2. ↑ 2.0 2.1 "National Centre for Neuroimmunology and Emerging Diseases". griffith.edu.au. Retrieved October 21, 2019.
  3. ↑ Cabanas, Helene; Muraki, Katsuhiko; Eaton-Fitch, Natalie; Staines, Donald Ross; Marshall-Gradisnik, Sonya (2021). "Potential Therapeutic Benefit of Low Dose Naltrexone in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Role of Transient Receptor Potential Melastatin 3 Ion Channels in Pathophysiology and Treatment". Frontiers in Immunology. 12: 687806. doi:10.3389/fimmu.2021.687806. ISSN 1664-3224. PMC 8313851. PMID 34326841.
  4. ↑ Maksoud, Rebekah; Eaton-Fitch, Natalie; Matula, Michael; Cabanas, Hélène; Staines, Donald; Marshall-Gradisnik, Sonya (May 2021). "Systematic Review of Sleep Characteristics in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome". Healthcare. 9 (5): 568. doi:10.3390/healthcare9050568.
  5. ↑ Cabanas, H.; Muraki, K.; Balinas, C.; Eaton-Fitch, N.; Staines, D.; Marshall-Gradisnik, S. (December 2019). "Validation of impaired Transient Receptor Potential Melastatin 3 ion channel activity in natural killer cells from Chronic Fatigue Syndrome/ Myalgic Encephalomyelitis patients". Molecular Medicine. 25 (1). doi:10.1186/s10020-019-0083-4. ISSN 1076-1551.
  6. ↑ Corbitt, Matthew; Eaton-Fitch, Natalie; Staines, Donald; Cabanas, Hélène; Marshall-Gradisnik, Sonya (December 2019). "A systematic review of cytokines in chronic fatigue syndrome/myalgic encephalomyelitis/systemic exertion intolerance disease (CFS/ME/SEID)". BMC Neurology. 19 (1). doi:10.1186/s12883-019-1433-0. ISSN 1471-2377. PMID 31445522.
  7. ↑ Cabanas, Helene; Muraki, Katsuhiko; Staines, Donald; Marshall-Gradisnik, Sonya (October 14, 2019). "Naltrexone restores impaired transient receptor potential melastatin 3 ion channel function in natural killer cells from myalgic encephalomyelitis/chronic fatigue syndrome patients". Frontiers in Immunology. doi:10.3389/fimmu.2019.02545.
  8. ↑ Balinas, Cassandra; Cabanas, Hélène; Staines, Donald; Marshall-Gradisnik, Sonya (December 3, 2019). "Transient receptor potential melastatin 2 channels are overexpressed in myalgic encephalomyelitis/chronic fatigue syndrome patients". Journal of Translational Medicine. 17 (1): 401. doi:10.1186/s12967-019-02155-4. ISSN 1479-5876. PMC 6891975. PMID 31796045.
  9. ↑ Marshall-Gradisnik, Sonya; Fretel, Marshall; Eaton, Natalie; Cabanas, Helene; Balinas, Cassandra; Gopalan, Vinod; Petersen, Daniel; Passmore, Rachel; Tang, Kevin; Haque, Mazhar; Lam, Alfred; Staines, Donald (May 31, 2018). "Decreased Expression of TRPM3 and mAChRM3 in the Small Intestine in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis". International Journal of Clinical Medicine. 09 (05): 467. doi:10.4236/ijcm.2018.95040.
  10. ↑ Du Preez, S.; Corbitt, M.; Cabanas, H.; Eaton, N.; Staines, D.; Marshall-Gradisnik, S. (December 20, 2018). "A systematic review of enteric dysbiosis in chronic fatigue syndrome/myalgic encephalomyelitis". Systematic Reviews. 7 (1): 241. doi:10.1186/s13643-018-0909-0. ISSN 2046-4053. PMID 30572962.
  11. ↑ Eaton, Natalie; Cabanas, Hélène; Balinas, Cassandra; Klein, Anne; Staines, Donald; Marshall-Gradisnik, Sonya (December 2018). "Rituximab impedes natural killer cell function in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients: A pilot in vitro investigation". BMC Pharmacology and Toxicology. 19 (1): 12. doi:10.1186/s40360-018-0203-8. ISSN 2050-6511. PMC 5870391. PMID 29587879.
  12. ↑ Cabanas, Hélène; Muraki, Katsuhiko; Eaton, Natalie; Balinas, Cassandra; Staines, Donald; Marshall-Gradisnik, Sonya (August 14, 2018). "Loss of Transient Receptor Potential Melastatin 3 ion channel function in natural killer cells from Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients". Molecular Medicine. 24 (1). doi:10.1186/s10020-018-0046-1. ISSN 1076-1551.

Concerning living organisms, such as cells or the human body.[1]  Physio logical (as in physio) is not to be confused with psych ological (emotional stress).

physiological Concerning living organisms, such as cells or the human body.  Physio logical (as in physio) is not to be confused with psych ological (emotional stress).

myalgic encephalomyelitis (M.E.) - A disease often marked by neurological symptoms, but fatigue is sometimes a symptom as well. Some diagnostic criteria distinguish it from chronic fatigue syndrome, while other diagnostic criteria consider it to be a synonym for chronic fatigue syndrome. A defining characteristic of ME is post-exertional malaise (PEM), or post-exertional neuroimmune exhaustion (PENE), which is a notable exacerbation of symptoms brought on by small exertions. PEM can last for days or weeks. Symptoms can include cognitive impairments, muscle pain (myalgia), trouble remaining upright (orthostatic intolerance), sleep abnormalities, and gastro-intestinal impairments, among others. An estimated 25% of those suffering from ME are housebound or bedbound. The World Health Organization (WHO) classifies ME as a neurological disease.

See ME/CFS.

systemic exertion intolerance disease (SEID) - A term for ME/CFS that aims to avoid the stigma associated with the term "chronic fatigue syndrome", while emphasizing the defining characteristic of post-exertional malaise (PEM). SEID was defined as part of the diagnostic criteria put together by the Institute of Medicine (IOM) report of 10 February 2015.

See systemic exertion intolerance disease.

Retrieved from "https://me-pedia.org/w/index.php?title=Hélène_Cabanas&oldid=234412"